Buy BioNTech SE at the low PE of 2.31

0
By:

Motiur Rahman

on
Jun 16, 2022

BioNTech expects EPS of $61 and has a forward PE of 2.31

The stock is pivoting at the sustainable support of $137

We strongly recommend buying BioNTech with a target price of $179

BioNTech SE (NASDAQ:BNTX) is trading at $137.99. The 52-week range has been $121 to $464. The stock is trading near the bottom, and we think it is a buy.

BioNTech is A-rated for value, growth, and momentum. It is a good fit for any of the three investment styles. However, technical analysis would point to a holding decision mainly because of the bear market. The return ratios for BioNTech are some of the highest in the industry. ROE was recorded at 144%, while the ROA is 108%. The high return ratios are expected to continue supporting the stock.


Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

Fundamental indicators suggest buying and holding the stock for the long term. BioNTech has a low forward PE of 2.31. This suggests that the stock is priced cheaply. Last year, the EPS was $49. This year’s EPS is expected at $61.

The return ratios for BioNTech are high and growing. The Achilles heel for the stock is the ability to grow sales. With COVID-19 vaccine sales declining, BioNTech will need to develop new products.

BioNTech consolidates between $137 and $179

Source – TradingView

BioNTech is consolidating between $137 and $179. At $137 the stock is at a support level. The MACD is mildly bullish. This analysis shows that BioNTech could pivot from the support and find the resistance level. At $137 the stock is definitely a buy.

Summary

BioNTech SE is a strong buy. The stock has high and growing ROE and EPS ratios. The PE of 2.31 indicates that the stock is cheaply valued by the market.

Where to buy right now

To invest simply and easily, users need a low-fee broker with a track record of reliability. The following brokers are highly rated, recognised worldwide, and safe to use:

Etoro, trusted by over 13m users worldwide. Register here >
Capital.com, simple, easy to use and regulated. Register here >

*Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

Biotech


Europe


Stocks & Shares

Generated by Feedzy